Please login to the form below

Not currently logged in
Email:
Password:

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

Engelbert Tjeenk Willink, member of the board of managing directors at Boehringer Ingelheim responsible for marketing and sales of prescription medicines, is to leave the German pharma company at the end of 2012.

He will be replaced by current head of established markets Allan Hillgrove, who takes over from January 1, 2013.

Tjeenk Willink has been in his current role since 2009, having originally joined Boehringer in 1994 as a medical director. Other positions he has held during his time at the company include head of marketing and sales in Canada, head of marketing for prescription medicines and country manager of Boehringer in Mexico.

Boehringer - Engelbert Tjeenk WillinkBoehringer - Allan Hillgrove

Engelbert Tjeenk Willink (left) and Allan Hillgrove (right)

“We are sorry to see him go and wish him all the best in his future professional and personal life,” said Christian Boehringer, chair of the shareholders committee, and Professor Andreas Barner, chair of the board, in a joint statement.

“Tjeenk Willink has worked with passion and enthusiasm for Boehringer Ingelheim. In his various roles in Ingelheim and abroad, he contributed significantly to the positive development of the group.”

His replacement, Hillgrove, has been with Boehringer since 1982, and has been in his current role since 2010.

“In his various roles he has helped to set the course for sustained growth in recent years,” said Boehringer and Barner in their joint statement.

“Shareholders and board members are convinced that with this staffing arrangement the board of managing directors will be well equipped for the various challenges that lie ahead for Boehringer Ingelheim and the research-driven pharmaceutical industry worldwide."

28th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Medical Communications

dna: as different as you. Every patient, disease and therapy is di­fferent. As is every message, stakeholder and educational challenge....

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...